Contraindicated. Coadministration of doravirine with a solid CYP3A inducer could lessen doravirine plasma concentrations and/or effects. Possible for lack of virologic reaction and feasible resistance to doravirine.pentobarbital will minimize the extent or influence of bexarotene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning